Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Cataract, is a clouding of the lens in the eye gradually leading to reduction of the visual acuity. In most cases it can be managed with surgery, removing the own lens and replacing it with an artificial lens, intraocular lens (IOL). These lenses are made in different materials with different properties.
Uveitis refers to an inflammation in the iris, ciliary body and choroid. Patients with this disease have an increased risk of developing cataract due to the inflammation itself and treatment with steroids. They also have an increased risk of complications during surgery and postoperatively. In this group the selection of IOL might be of greater importance.
The aim of this prospective randomized controlled study is to compare the outcome of hydrophobic and hydrophilic intraocular lenses in patients with and without uveitis
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Hydrophobic IOL: Vivinex (HOYA) | Other | Intraocular lens with hydrophobic properties: Vivinex (HOYA). |
|
| Hydrophilic IOL: INCISE (Bausch+Lomb) | Other | Intraocular lens with hydrophilic properties: INCISE (Bausch+Lomb). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Hydrophobic IOL: Vivinex (HOYA) | Device | Patients requiring cataract surgery will be randomized to one of the two types of IOLs. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in inflammatory response | Preoperatively and at seven occasions within two years postoperatively |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of posterior capsule opacification after six months | Six months (plus or minus 30 days) postoperatively | |
| Evaluation of posterior capsule opacification after one year | One year (plus or minus 30 days) postoperatively |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Madeleine Zetterberg, MD, PhD | Västra Götalands regionen, Sahlgrenska University Hospital, Department of Ophthalmology | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Vastra Gotaland Region, Sahlgrenska University Hospital, Department of Ophthalmology | Mölndal | Sweden |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014605 | Uveitis |
| D002386 | Cataract |
| D007249 | Inflammation |
| ID | Term |
|---|---|
| D014603 | Uveal Diseases |
| D005128 | Eye Diseases |
| D007905 | Lens Diseases |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Hydrophilic IOL: INCISE (Bausch+Lomb) | Device | Patients requiring cataract surgery will be randomized to one of the two types of IOLs. |
|
| Evaluation of posterior capsule opacification after two years | Two years (plus or minus 2 months) postoperatively |
| Change in best corrected visual acuity assessed in decimal using Snellen charts | Preoperatively and at six occasions within two years postoperatively |
| Complications | Postoperative glaucoma or cystoid macular edema | Preoperatively and at seven occasions within two years postoperatively |
| D013568 |
| Pathological Conditions, Signs and Symptoms |